CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 Blood Work Labs Monitor — What to Track

Real Peptides Research TeamEditorial

Updated April 30, 202611 min read

59 WORDS

Short answer

Key takeaways

IGF-1 is the only direct measure of CJC-1295 efficacy. Without it, you're dosing blind and can't distinguish responders from non-responders.
Fasting glucose and HbA1c must be monitored because growth hormone impairs insulin sensitivity, increasing diabetes risk in susceptible individuals.
Liver enzymes (AST, ALT) track hepatic stress from peptide metabolism. Elevations above 60 U/L warrant dose reduction or discontinuation.
Prolactin elevation occurs in 5–10% of GHRH analogue users and can cause gynecomastia, libido suppression, and erectile dysfunction if undetected.
Draw IGF-1 at 4–6 weeks minimum. Testing earlier produces spuriously low results because hepatic IGF-1 synthesis takes 28–35 days to reach steady state.
Lipid panels typically show improved triglycerides and HDL during GH elevation, but transient LDL rises during weeks 4–12 as stored fat mobilises.
A thyroid panel (TSH, Free T3, Free T4) at baseline and 12 weeks identifies whether GH elevation suppresses thyroid function or alters hormone conversion.

Research facilities using CJC-1295 (a growth hormone-releasing hormone analogue) routinely track IGF-1 levels. The downstream biomarker that confirms whether the peptide is driving pituitary GH secretion as intended. Yet most individual research protocols omit this entirely, relying instead on subjective markers like recovery time or body composition changes that could be confounded by diet, training load, or placebo effect. A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that IGF-1 response to exogenous GHRH analogues varied by more than 300% between subjects at identical doses. Without blood work, you have no way of knowing whether your dose is producing the intended biological cascade or whether you're a non-responder.

Our team has worked with research-grade peptides for years, and we've seen the same pattern repeatedly: protocols that skip baseline and follow-up blood work produce inconsistent outcomes that can't be interpreted meaningfully. The gap between doing CJC-1295 blood work labs monitor protocols correctly and winging it comes down to three things most guides never mention. Baseline IGF-1 timing, liver enzyme tracking during dose titration, and glucose monitoring in subjects with impaired insulin sensitivity.

What blood work should you monitor when using CJC-1295 in research protocols?

CJC-1295 blood work labs monitor protocols should include baseline and follow-up IGF-1 levels (the primary efficacy marker), fasting glucose and HbA1c (because GH elevation impairs insulin sensitivity), lipid panel (GH increases lipolysis and can alter lipid profiles), liver enzymes AST and ALT (peptides are metabolised hepatically), and prolactin (GHRH analogues can stimulate lactotroph cells). IGF-1 should be measured 4–6 weeks after starting CJC-1295 to assess pituitary response, then every 8–12 weeks during continued use.

Yes, CJC-1295 blood work labs monitor protocols require more than just IGF-1. But IGF-1 is non-negotiable. Growth hormone itself has a half-life of 20–30 minutes and exhibits pulsatile secretion, making direct GH measurement impractical for outpatient monitoring. IGF-1, synthesised in the liver in response to GH, has a half-life of 12–15 hours and provides a stable, integrated measure of GH activity over days. The rest of this piece covers exactly which labs matter, why they matter mechanistically, what reference ranges mean in the context of peptide research, and what preparation mistakes invalidate results entirely.

Why IGF-1 Is the Primary CJC-1295 Efficacy Marker

CJC-1295 works by binding to growth hormone-releasing hormone (GHRH) receptors on somatotroph cells in the anterior pituitary, triggering pulsatile GH release without suppressing endogenous GHRH production the way exogenous GH does. The intended outcome. Elevated GH. Drives hepatic synthesis of IGF-1, which mediates most of GH's anabolic, lipolytic, and metabolic effects. Without measuring IGF-1, you're inferring GH elevation from secondary markers (body composition, recovery, subjective energy) that are influenced by dozens of confounding variables.

IGF-1 reference ranges are age- and sex-dependent. A 25-year-old male typically sits between 180–360 ng/mL, while a 50-year-old male averages 90–200 ng/mL. CJC-1295 responders typically see IGF-1 rise by 30–80% from baseline within 4–6 weeks at therapeutic doses (1–2 mg weekly for modified CJC-1295 with DAC, the Drug Affinity Complex that extends half-life to approximately 8 days). Non-responders. Who comprise roughly 10–15% of research populations based on clinical GHRH analogue studies. Show minimal or no IGF-1 elevation despite adequate dosing, often due to pituitary hyporesponsiveness or hepatic IGF-1 synthesis impairment.

The critical timing mistake most protocols make: drawing IGF-1 fewer than four weeks after initiating CJC-1295. Hepatic IGF-1 synthesis ramps gradually. Peak steady-state levels aren't reached until 28–35 days of consistent GH elevation. Drawing at week two produces spuriously low results that don't reflect true efficacy.

CJC-1295 Blood Work Labs Monitor: Complete Panel Breakdown

A comprehensive CJC-1295 blood work labs monitor protocol includes six core markers, each tracking a distinct physiological pathway affected by growth hormone elevation. This isn't a shotgun approach. Every marker on this panel answers a specific question about safety, efficacy, or metabolic adaptation.

IGF-1 (Insulin-Like Growth Factor 1): Primary efficacy marker. Measures hepatic response to pituitary GH secretion. Draw baseline before starting CJC-1295, then at 4–6 weeks, 12 weeks, and every 8–12 weeks during continued use. Reference range: 180–360 ng/mL for males aged 20–30, 90–200 ng/mL for males aged 45–55. Expect 30–80% elevation from baseline in responders.

Fasting Glucose and HbA1c: GH is a counter-regulatory hormone that opposes insulin action. Chronic elevation impairs glucose tolerance. Fasting glucose should remain below 100 mg/dL; HbA1c below 5.7%. Subjects with pre-existing insulin resistance (fasting glucose 100–125 mg/dL or HbA1c 5.7–6.4%) are at higher risk for progression to overt diabetes during GH elevation and require more frequent monitoring (every 6–8 weeks).

Lipid Panel (Total Cholesterol, LDL, HDL, Triglycerides): GH increases lipolysis and shifts substrate utilisation toward fat oxidation, typically lowering triglycerides and raising HDL. LDL may rise transiently during the first 8–12 weeks as stored lipids mobilise. A lipid panel at baseline and 12 weeks captures this metabolic shift. Persistent LDL elevation above 160 mg/dL warrants dietary intervention or dose adjustment.

Liver Enzymes (AST, ALT): Peptides are metabolised hepatically, and CJC-1295 increases hepatic workload through IGF-1 synthesis. AST and ALT should remain below 40 U/L. Elevations above 60 U/L without other explanation (alcohol, medications, viral hepatitis) may indicate hepatic stress and require dose reduction or discontinuation.

Prolactin: GHRH analogues can stimulate lactotroph cells in the pituitary, elevating prolactin in 5–10% of users. Prolactin above 20 ng/mL in males can cause gynecomastia, libido suppression, and erectile dysfunction. Baseline prolactin establishes whether elevation is peptide-related or pre-existing.

Thyroid Panel (TSH, Free T3, Free T4): GH and IGF-1 influence thyroid hormone metabolism. Some research suggests GH elevation can suppress TSH or alter peripheral T4-to-T3 conversion. A thyroid panel at baseline and 12 weeks identifies whether thyroid function remains stable or requires intervention.

CJC-1295 Blood Work Labs Monitor: Comparison of Testing Protocols

This table compares three common CJC-1295 blood work labs monitor approaches. Minimal, standard, and comprehensive. Showing what each protocol tracks, when labs are drawn, and what each protocol misses.

Protocol Type	Markers Tracked	Testing Frequency	What It Catches	What It Misses	Professional Assessment
Minimal (IGF-1 Only)	IGF-1	Baseline + Week 6	Confirms pituitary response to CJC-1295	Glucose dysregulation, liver stress, lipid changes, prolactin elevation	Confirms efficacy but provides no safety data. High risk for undetected metabolic side effects
Standard (IGF-1 + Metabolic)	IGF-1, fasting glucose, HbA1c, lipid panel	Baseline + Week 6 + Week 12	Efficacy + glucose/lipid shifts over 12 weeks	Liver enzyme elevation, prolactin issues, thyroid suppression	Balances safety and cost. Appropriate for healthy subjects with no metabolic risk factors
Comprehensive (Full Panel)	IGF-1, glucose, HbA1c, lipids, AST/ALT, prolactin, TSH/T3/T4	Baseline + Week 6 + Week 12 + Every 12 weeks	Full metabolic, hepatic, endocrine picture throughout protocol	Nothing. Captures all clinically relevant pathways affected by GH elevation	Gold standard for research protocols. Especially critical for subjects over 40 or those with pre-existing metabolic conditions

What If: CJC-1295 Blood Work Labs Monitor Scenarios

What If My IGF-1 Doesn't Rise After Six Weeks on CJC-1295?

Reduce dose temporarily and retest at eight weeks. Some individuals require longer to reach steady-state IGF-1 elevation, especially those over 45 with age-related declines in hepatic IGF-1 synthesis capacity. Non-response (less than 15% IGF-1 increase from baseline after eight weeks at 1–2 mg weekly) occurs in roughly 10–15% of subjects and typically reflects pituitary hyporesponsiveness rather than peptide quality issues. If IGF-1 remains flat, consider switching to a GH secretagogue with a different mechanism (like ipamorelin or MK-677, which work through ghrelin receptors rather than GHRH receptors) or discontinuing the protocol entirely.

What If My Fasting Glucose Rises Above 110 mg/dL During CJC-1295 Use?

This is an expected metabolic consequence of chronic GH elevation. Growth hormone antagonises insulin action at the cellular level, reducing glucose uptake into muscle and adipose tissue. If fasting glucose rises from 90 mg/dL to 110 mg/dL, implement carbohydrate restriction (limit intake to under 150g daily), increase aerobic activity (which improves insulin sensitivity independent of GH), and retest glucose and HbA1c in four weeks. If glucose exceeds 125 mg/dL or HbA1c rises above 6.0%, discontinue CJC-1295 immediately. You're at risk for progression to overt type 2 diabetes.

What If My Liver Enzymes (AST/ALT) Elevate to 50–60 U/L?

Temporary enzyme elevation during the first 6–8 weeks can reflect increased hepatic workload from IGF-1 synthesis rather than true hepatotoxicity. Retest in four weeks without dose changes to establish trend. If enzymes remain stable or decline, continue monitoring every eight weeks. If they rise above 70 U/L or double from baseline, reduce CJC-1295 dose by 50% and retest in two weeks. Persistent elevation above 80 U/L despite dose reduction is grounds for discontinuation and hepatic ultrasound to rule out fatty liver or other pathology.

What If My Prolactin Rises to 25 ng/mL (Normal Male Range: 4–15 ng/mL)?

Prolactin elevation above 20 ng/mL in males can cause gynecomastia (breast tissue development), reduced libido, and erectile dysfunction through suppression of gonadotropin-releasing hormone (GnRH) signalling. If prolactin rises modestly (20–30 ng/mL) without symptoms, reduce CJC-1295 dose by 30–50% and retest in four weeks. Many cases resolve with dose adjustment. If prolactin exceeds 30 ng/mL or symptoms develop, discontinue CJC-1295 and consider cabergoline (a dopamine agonist that lowers prolactin) under medical supervision.

The Blunt Truth About CJC-1295 Blood Work Labs Monitor

Here's the honest answer: most peptide protocols fail not because the compound doesn't work, but because users skip the blood work that would tell them whether it's working. You can't feel IGF-1 levels. Subjective improvements in recovery or body composition can be placebo, diet changes, training adaptations, or a dozen other variables. Without baseline and follow-up IGF-1, you're spending money on a compound whose efficacy you can't verify. The single biggest mistake we see across research protocols: drawing labs once at week three, seeing modest IGF-1 elevation, then never retesting. Missing the glucose dysregulation at week ten or the liver enzyme spike at week fourteen that would have prompted dose adjustment. CJC-1295 blood work labs monitor isn't optional infrastructure. It's the only way to distinguish signal from noise in peptide research.

How Lab Timing Affects CJC-1295 Blood Work Accuracy

Lab timing errors are the most common reason CJC-1295 blood work labs monitor protocols produce misleading results. IGF-1 has a circadian rhythm. Levels peak in the early morning and decline throughout the day by 15–20%. Drawing IGF-1 at 8 AM on the baseline test and 3 PM on the follow-up test introduces a systematic error that could mask a real 30% increase or falsely suggest an increase where none exists. All IGF-1 draws should occur at the same time of day, ideally between 7–9 AM after an overnight fast.

Fasting glucose must be drawn after at least eight hours without caloric intake. Non-fasting glucose is useless for assessing insulin sensitivity. HbA1c, which reflects average glucose over the previous 90 days, doesn't require fasting and isn't affected by time of day, making it the more reliable long-term metabolic marker. Lipid panels require 12-hour fasting to produce accurate triglyceride measurements. Non-fasting triglycerides can be 50–100 mg/dL higher than true fasting levels, invalidating comparisons between baseline and follow-up.

Liver enzymes (AST, ALT) are relatively stable throughout the day but can be transiently elevated by intense resistance training. Avoid drawing liver enzymes within 48 hours of a heavy squat or deadlift session. Prolactin is highly sensitive to stress and physical activity. Subjects should be seated and rested for at least 15 minutes before the draw to avoid spuriously elevated results.

Real Peptides produces research-grade peptides with verified amino-acid sequencing and purity exceeding 98%. But even the highest-purity compound can't compensate for poorly timed or improperly collected blood work. Our experience working with research facilities shows that timing errors are more common than peptide quality issues when protocols produce inconsistent outcomes. If you're investing in CJC1295 Ipamorelin 5MG 5MG or other research compounds, the lab protocol deserves the same attention as peptide selection.

The single lab timing rule that invalidates more CJC-1295 blood work labs monitor results than any other: drawing IGF-1 before four weeks of consistent dosing. Hepatic IGF-1 synthesis takes 28–35 days to reach steady state. Early draws underestimate true efficacy by 30–50%. Wait the full four weeks. The data will be worth it.

If your CJC-1295 blood work labs monitor protocol doesn't include IGF-1 at baseline and follow-up, fasting glucose to track insulin sensitivity, and liver enzymes to rule out hepatic stress. Raise it before starting dosing. Establishing these parameters costs nothing extra upfront and matters across a 12–24 week research protocol.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Draw IGF-1 at baseline before starting CJC-1295, then at 4–6 weeks to assess initial response, at 12 weeks to confirm sustained elevation, and every 8–12 weeks during continued use to monitor for tolerance or pituitary desensitisation. Testing more frequently than every four weeks provides no additional information because IGF-1 levels stabilise slowly over 28–35 days and fluctuate minimally week-to-week once steady state is reached.

Baseline fasting glucose of 105 mg/dL falls in the prediabetic range (100–125 mg/dL), meaning you already have impaired insulin sensitivity before introducing a compound that worsens glucose tolerance. CJC-1295 elevates growth hormone, which antagonises insulin action and raises fasting glucose by 10–20 mg/dL in susceptible individuals — starting from 105 mg/dL puts you at high risk for crossing into overt diabetes (fasting glucose above 126 mg/dL) within 8–12 weeks. If you proceed, monitor glucose and HbA1c every six weeks rather than every 12, and discontinue immediately if glucose exceeds 120 mg/dL.

IGF-1 elevation confirms that CJC-1295 is driving pituitary GH secretion and hepatic IGF-1 synthesis as intended — the peptide is working at the hormonal level. Subjective benefits like improved recovery, body composition changes, or energy increases depend on training stimulus, caloric intake, sleep quality, and baseline fitness level — all of which confound perception of peptide efficacy. A 40% IGF-1 increase from baseline is biologically meaningful even if you ‘don’t feel different,’ and many adaptations (increased collagen synthesis, improved bone density, enhanced lipolysis) occur below the threshold of conscious awareness.

No — CJC-1295 should not be discontinued before blood work because you’re measuring the steady-state hormonal effect of the peptide, not an acute response. Stopping CJC-1295 for several days before drawing IGF-1 produces a declining or intermediate result that doesn’t reflect true on-peptide levels. The only exception is prolactin: if prolactin is elevated and you’re trying to distinguish peptide-induced elevation from a pre-existing condition, discontinue CJC-1295 for four weeks and retest to see if prolactin normalises.

Growth hormone (GH) has a half-life of 20–30 minutes and is secreted in pulses throughout the day, making a single random GH draw nearly useless — you could catch a pulse (falsely high result) or a trough (falsely low result) depending on timing. IGF-1, synthesised in the liver in response to GH, has a half-life of 12–15 hours and provides a stable, integrated measure of GH activity over days. For CJC-1295 monitoring, IGF-1 is the only practical and reliable marker — direct GH measurement is reserved for specialised endocrine testing in clinical settings.

IGFBP-3 (insulin-like growth factor binding protein 3) is the primary carrier protein for IGF-1 in circulation — approximately 80% of circulating IGF-1 is bound to IGFBP-3, which prolongs its half-life and regulates its bioavailability. Some endocrinologists measure both IGF-1 and IGFBP-3 to calculate the IGF-1/IGFBP-3 ratio, which may provide additional insight into GH activity in cases where IGF-1 alone is ambiguous. For most CJC-1295 research protocols, IGF-1 alone is sufficient — IGFBP-3 adds cost without meaningfully changing interpretation in healthy subjects with normal hepatic function.

Mild transient elevation of AST and ALT (up to 60 U/L) during the first 8–12 weeks of CJC-1295 use reflects increased hepatic workload from IGF-1 synthesis and typically resolves without intervention or long-term consequences. Persistent elevation above 80 U/L or progressive increases over time can indicate hepatic stress that, if unaddressed, may progress to steatosis (fatty liver) or more serious pathology. The key is monitoring — catching enzyme elevation early allows dose adjustment or discontinuation before permanent damage occurs, which is why liver enzymes should be checked at baseline, week 6, and week 12 at minimum.

IGF-1 levels decline gradually after discontinuing CJC-1295, typically returning to baseline within 4–6 weeks as pituitary GH secretion normalises and hepatic IGF-1 synthesis downregulates. Fasting glucose usually improves within 2–3 weeks as insulin sensitivity recovers once GH-mediated antagonism of insulin action ceases. Liver enzymes normalise within 4–8 weeks if they were elevated during peptide use. Prolactin, if elevated, typically returns to baseline within 6–8 weeks after discontinuation — if prolactin remains elevated beyond eight weeks off-peptide, further investigation for a pituitary microadenoma or other cause is warranted.

IGF-1 response guides dose titration in research protocols — if IGF-1 rises by only 15–20% from baseline at 1 mg weekly after six weeks, increasing to 1.5–2 mg weekly may produce a more robust response. Conversely, if IGF-1 rises by more than 100% (doubling from baseline), consider reducing dose by 30–50% to avoid supraphysiological GH exposure, which increases risk for glucose dysregulation, joint pain, and soft tissue edema. The goal is to elevate IGF-1 into the upper half of the age-appropriate reference range (e.g., 250–320 ng/mL for a 30-year-old male with a reference range of 180–360 ng/mL) rather than maximising IGF-1 at any cost.

If you’re stacking CJC-1295 with ipamorelin, GHRP-2, or other GH secretagogues, the core CJC-1295 blood work labs monitor panel remains the same — IGF-1 is still the primary efficacy marker regardless of which combination of peptides drives GH secretion. The main additional consideration is prolactin: GHRP-2 and hexarelin elevate prolactin more aggressively than CJC-1295 alone, so baseline and follow-up prolactin monitoring becomes even more critical in stacked protocols. Glucose and liver enzyme monitoring remain essential because stacking peptides doesn’t reduce metabolic or hepatic impact — it may amplify it.

HbA1c reflects average glucose control over the previous 90 days and is less susceptible to day-to-day variability than fasting glucose, making it the more reliable long-term metabolic marker — a single fasting glucose of 115 mg/dL could be an anomaly, but an HbA1c of 6.0% confirms sustained glucose elevation over months. However, fasting glucose responds more quickly to metabolic changes, making it useful for detecting early insulin resistance during the first 6–12 weeks of CJC-1295 use before HbA1c has time to shift. Optimal CJC-1295 blood work labs monitor protocols include both — fasting glucose at baseline, week 6, and week 12, plus HbA1c at baseline and week 12.

At-home finger-stick tests are acceptable for fasting glucose monitoring (using a standard glucometer) but are inadequate for IGF-1, liver enzymes, lipid panels, and prolactin — these require venous blood draws and laboratory analysis with calibrated assays. Some direct-to-consumer lab companies offer at-home phlebotomy services where a technician draws venous blood at your location and ships it to a certified lab, which provides the accuracy of traditional lab work with the convenience of home testing. For research protocols requiring precise IGF-1 quantification and comprehensive metabolic panels, venous lab draws are non-negotiable — finger-stick tests lack the sensitivity and specificity needed for peptide monitoring.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA